Possible inhibitory effect of oral zinc supplementation on hepatic fibrosis through downregulation of TIMP-1: A pilot study

Masahiko Takahashi, Hidetsugu Saito, Makiko Higashimoto, Toshifumi Hibi

Research output: Contribution to journalArticlepeer-review

43 Citations (Scopus)

Abstract

Aim: To investigate the effect of oral zinc supplementation (polaprezinc) for 24 weeks (34 mg/day zinc) on liver fibrosis in patients with advanced chronic liver disease. Methods: Various markers of liver fibrosis, and fibrogenic and fibrolytic enzyme activities were measured before and after zinc supplementation in 17 patients with early cirrhosis. Results: Serum zinc levels were decreased in the patients as compared with healthy controls. No side-effect was noted in any of the patients who received zinc supplementation. Serum levels of zinc increased by up to 156% over baseline levels in the group of patients who took oral zinc for 24 weeks. In patients whose serum zinc levels increased, the serum levels of type IV collagen and the activity of tissue inhibitors of metalloproteinase-1 (TIMP-1) were significantly reduced, but no such change was observed in the other groups of patients, and no other serum markers changed. Conclusion: These results suggest that oral zinc supplement therapy with polaprezinc is safe and may be a novel and useful strategy for antifibrosis therapy in patients with early liver cirrhosis.

Original languageEnglish
Pages (from-to)405-409
Number of pages5
JournalHepatology Research
Volume37
Issue number6
DOIs
Publication statusPublished - 2007 Jun 1

Keywords

  • Hepatic fibrosis
  • Polapre zinc
  • TIMP-1
  • Zinc

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Possible inhibitory effect of oral zinc supplementation on hepatic fibrosis through downregulation of TIMP-1: A pilot study'. Together they form a unique fingerprint.

Cite this